octenyl succinic anhydride | 7757-96-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: octenyl succinic anhydride
• 英文别名: octenylsuccinic acid anhydride；3-Octenylsuccinic anhydride；3-oct-1-enyloxolane-2,5-dione
• CAS: 7757-96-2
• 化学式: C₁₂H₁₈O₃
• 分子量: 210.273
• InChiKey: FLISWPFVWWWNNP-UHFFFAOYSA-N

物化性质

• 沸点：
  328.2±31.0 °C(Predicted)
• 密度：
  1.099±0.06 g/cm3(Predicted)
• LogP：
  2.650 (est)
• 物理描述：
  Liquid

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  octenyl succinic anhydride 、 2,2,6,6-四甲基哌啶胺 在 溶剂黄146 、 丙酮 作用下， 以 溶剂黄146 为溶剂， 反应 3.0h， 以155.2 g of a colorless powder were obtained的产率得到3-octenyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)succinimide
  参考文献：
  名称：

  Dermocosmetic Preparations

  摘要：

  本发明涉及含有以下结构元素的皮肤化妆品组合物：式I中的基团Z具有以下含义：H、C1-C22烷基、C6-C10芳基、C1-C22烷氧基或被C1-C22烷基或C-C22烷氧基取代的C6-C10-O-芳基；基团R1至R6独立地具有以下含义：H、C1-C22烷基、C6-C10芳基、O、OH、C1-C22烷氧基或被C1-C22烷基或C1-C22烷氧基取代的C6-C10-O-芳基；其中R5和R6可以被桥接，形成五至八元环，且在五元环的情况下，由于在3和4位置的共价键而成为寡聚体的一部分。本发明还涉及所述化合物在皮肤化妆品配方中的使用以及根据本发明的皮肤化妆品的使用，用于减少由自由基引起的皮肤或头发损伤。本发明还涉及使用本发明的化合物以增加皮肤化妆品配方的稳定性。

  公开号：

  US20080220031A1

文献信息

• USE OF NITROGEN COMPOUNDS QUATERNISED WITH ALKYLENE OXIDE AND HYDROCARBYL-SUBSTITUTED POLYCARBOXYLIC ACID AS ADDITIVES IN FUELS AND LUBRICANTS
  申请人：BASF SE

  公开号：US20160130514A1

  公开（公告）日：2016-05-12

  The invention relates to the use of quaternized nitrogen compounds as a fuel and lubricant additive or kerosene additive, such as in particular as a detergent additive, for decreasing or preventing deposits in the injection systems of direct-injection diesel engines, in particular in common rail injection systems, for decreasing the fuel consumption of direct-injection diesel engines, in particular of diesel engines having common rail injection systems, and for minimizing the power loss in direct-injection diesel engines, in particular in diesel engines having common rail injection systems; the invention further relates to the use as an additive for petrol, in particular for operation of DISI engines.

  该发明涉及将季铵化氮化合物用作燃料和润滑剂添加剂或煤油添加剂，特别是作为清洁剂添加剂，用于减少或预防直喷柴油发动机的喷射系统中的沉积物，在特定是在共轨喷射系统中，用于降低直喷柴油发动机的燃料消耗，特别是具有共轨喷射系统的柴油发动机，并用于减少直喷柴油发动机的功率损失，特别是在具有共轨喷射系统的柴油发动机中；该发明还涉及将其用作汽油添加剂，特别是用于DISI发动机的运行。
• BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
  申请人：SENOMYX, INC.

  公开号：US20160376263A1

  公开（公告）日：2016-12-29

  The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.

  本发明涵盖已知用于改变苦味感知的化合物和组合物，以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种：冷却剂；无活性药物成分；活性药用成分；食品添加剂或食品；调味剂或调味增强剂；食品或饮料产品；苦味化合物；甜味剂；苦味剂；酸味调味剂；咸味调味剂；鲜味调味剂；植物或动物产品；已知用于宠物护理产品中的化合物；已知用于个人护理产品中的化合物；已知用于家用产品中的化合物；制药制剂；局部制剂；大麻衍生或与大麻相关的产品；已知用于口腔护理产品中的化合物；饮料；香味、香水或除臭剂；已知用于消费品中的化合物；硅化合物；磨料；表面活性剂；发热剂；吸烟物品；脂肪、油脂或乳化剂；和/或益生菌或补充剂。
• Biodegradable ocular implants and methods for treating ocular conditions
  申请人：Burkstrand J. Michael

  公开号：US20080089923A1

  公开（公告）日：2008-04-17

  Biodegradable ocular implants are described. The ocular implants include a bioactive agent that can be released within the eye to treat an ocular condition or indication. The implants can be used for the administration of a bioactive agent over prolonged periods of time. In some aspects the implants are formed of a matrix of natural biodegradable polysaccharides.

  可降解眼部植入物被描述。这些眼部植入物包括可以在眼内释放的生物活性剂，用于治疗眼部疾病或症状。这些植入物可用于在较长时间内给药生物活性剂。在某些方面，这些植入物由天然可降解多糖的基质形成。
• Sun protection compositions comprising semi-crystalline polymers and hollow latex particles
  申请人：Candau Didier

  公开号：US20090041691A1

  公开（公告）日：2009-02-12

  Topically applicable cosmetic/dermatological UV protection compositions having enhanced SPF contain at least one organic UV screening agent and/or at least one inorganic screening agent, such compositions also containing at least the following constituents (A) and (B): A) a semi-crystalline polymer which is solid at ambient temperature and has a melting point of greater than or equal to 30° C., containing a) a polymeric backbone and b) at least one crystallizable organic side chain and/or one crystallizable organic block forming part of the backbone of this said polymer, said polymer having a number-average molecular mass Mn of greater than or equal to 1,000, and B) hollow latex particles having a particle size ranging from 150 to 380 nm, formulated into a topically applicable, physiologically acceptable medium therefor.

  具有增强SPF的适用于化妆品/皮肤科的防紫外线保护组合物至少包含一种有机紫外线过滤剂和/或至少一种无机过滤剂，此类组合物还至少包含以下成分（A）和（B）： A）半结晶聚合物，室温下为固体，熔点大于或等于30°C，包含a）聚合骨架和b）至少一种可结晶有机侧链和/或作为该聚合物骨架一部分的可结晶有机块，该聚合物具有大于或等于1,000的数均分子质量Mn，以及 B）中空乳胶颗粒，粒径范围为150至380纳米，配制成适用于局部使用的、生理上可接受的介质。
• Polypeptide microparticles having sustained release characteristics, methods and uses
  申请人：Slager Joram

  公开号：US20090022805A1

  公开（公告）日：2009-01-22

  The invention provides polypeptide microparticles having control release features, particular methods for the preparation of such microparticles, and drug delivery systems that include polypeptide microparticles.

  这项发明提供了具有控制释放特性的多肽微粒，以及用于制备这种微粒的特定方法，以及包括多肽微粒的药物输送系统。